NET-02: A multicenter, randomized, phase II trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients (pts) with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma (PD-EP-NEC)
McNamara, Mairead G Swain, J. Craig, Z. Sharma, R. Faluyi, O. O. Wadsley, J. Morgan, C. Wall, L. R. Chau, I. Reed, N.
McNamara, Mairead G
Swain, J.
Craig, Z.
Sharma, R.
Faluyi, O. O.
Wadsley, J.
Morgan, C.
Wall, L. R.
Chau, I.
Reed, N.
Citations
Altmetric:
Abstract
Description
Date
2022
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
McNamara MG, Swain J, Craig Z, Sharma R, Faluyi OO, Wadsley J, et al. NET-02: A multicenter, randomized, phase II trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients (pts) with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma (PD-EP-NEC). Journal of Clinical Oncology. 2022 Jun;40(16). PubMed PMID: WOS:000863680301173.